AUSTIN,
Texas, Aug. 19, 2024 /PRNewswire/ -- Aileron
Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical
company advancing a novel pipeline of first-in-class medicines to
address significant unmet medical needs in orphan pulmonary and
fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief
Executive Officer of Aileron, will present at the 8th
Annual IPF Summit taking place August 20-22,
2024 in Boston, MA.
Details of the presentation are as follows:
Presentation Title: Biomarker Strategies in the Clinical
Development of LTI-03 in IPF
Session: Emerging Biology & Early Translation |
Uncovering a Translational Framework of Preclinical Modelling to
Enhance the Predictive Power & Navigate from Bench to Bedside
for the Next-Gen Therapeutics
Date &
Time: Wednesday, August 21,
2024, at 2:45 PM ET
The IPF Summit is the largest drug development initiative for
the pulmonary fibrosis community, bringing together key
biopharmaceutical companies, clinicians, and academic researchers
from around the globe. For more information about the IPF Summit,
please visit ipf-summit.com.
About Aileron Therapeutics
Aileron Therapeutics is a biopharmaceutical company
advancing a novel pipeline of first-in-class medicines to address
significant unmet medical needs in orphan pulmonary and fibrosis
indications. Aileron's lead product candidate, LTI-03, is a novel,
synthetic peptide with a dual mechanism targeting alveolar
epithelial cell survival as well as inhibition of profibrotic
signaling. Currently, LTI-03 is being evaluated in a Phase
1b clinical trial for the treatment
of idiopathic pulmonary fibrosis, with Cohort 2 results expected to
be reported in the third quarter this year. Aileron's second
product candidate, LTI-01, is a proenzyme that has completed Phase
1b and Phase 2a clinical trials for
the treatment of loculated pleural effusions. LTI-01 has received
Orphan Drug Designation in the US and EU and Fast Track Designation
in the US.
Investor Relations & Media Contact:
Argot
Partners
aileron@argotpartners.com
212-600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aileron-therapeutics-to-present-at-the-8th-annual-ipf-summit-302225421.html
SOURCE Aileron Therapeutics, Inc.